AI Article Synopsis
- Mammalian target of rapamycin inhibitors (mTORi), like sirolimus and everolimus, are medications used for treating certain cancers and in organ transplant procedures.
- Interstitial lung disease (ILD) is a potential complication associated with mTORi, with more cases linked to sirolimus compared to everolimus, possibly due to sirolimus being more widely used earlier on.
- A specific case is presented where a kidney transplant patient developed ILD from sirolimus but showed quick improvement after switching to everolimus.
Article Abstract
Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sirolimus than with everolimus in the literature, possibly due to earlier introduction and wider use of sirolimus. We report the case of a kidney transplant recipient who developed ILD secondary to sirolimus and improved rapidly after switching to everolimus.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287142 | PMC |
| http://dx.doi.org/10.1016/j.rmcr.2020.101109 | DOI Listing |
Publication Analysis
Top Keywords
interstitial lung
8
lung disease
8
sirolimus-induced interstitial
4
disease resolution
4
resolution conversion
4
conversion everolimus
4
everolimus mammalian
4
mammalian target
4
target rapamycin
4
rapamycin inhibitors
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!